Novartis Must Note Blood Pressure Drug Risks On EU Labels

Law360, New York (February 17, 2012, 7:00 PM EST) -- A European regulator warned on Friday that Novartis AG’s blood pressure drug Rasilez should not be prescribed to certain patients with Type 1 or Type 2 diabetes or kidney problems, and called for warnings to be included in the labeling of such medications in the European Union.

The European Medicines Agency said its review of Novartis' aliskiren-containing medications, including Rasilez, had shown that they should not be prescribed to patients taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers if they have diabetes or kidney impairment...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.